Therapeutic anti-C5 monoclonal antibodies (e.g. Eculizumab) are used in a variety of conditions such as atypical haemolytic uraemic syndrome and paroxysmal nocturnal haemoglobinuria and by design induce an acquired terminal pathway complement deficiency. This evidence concerns the gene C5 and complement deficiency.